184 related articles for article (PubMed ID: 22234518)
1. Molecular insights on basal-like breast cancer.
Valentin MD; da Silva SD; Privat M; Alaoui-Jamali M; Bignon YJ
Breast Cancer Res Treat; 2012 Jul; 134(1):21-30. PubMed ID: 22234518
[TBL] [Abstract][Full Text] [Related]
2. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
[TBL] [Abstract][Full Text] [Related]
3. c-Kit expression as a prognostic molecular marker in patients with basal-like breast cancer.
Kashiwagi S; Yashiro M; Takashima T; Aomatsu N; Kawajiri H; Ogawa Y; Onoda N; Ishikawa T; Wakasa K; Hirakawa K
Br J Surg; 2013 Mar; 100(4):490-6. PubMed ID: 23319435
[TBL] [Abstract][Full Text] [Related]
4. What is the difference between triple-negative and basal breast cancers?
Seal MD; Chia SK
Cancer J; 2010; 16(1):12-6. PubMed ID: 20164685
[TBL] [Abstract][Full Text] [Related]
5. Basal phenotype breast cancer: implications for treatment and prognosis.
Pazaiti A; Fentiman IS
Womens Health (Lond); 2011 Mar; 7(2):181-202. PubMed ID: 21410345
[TBL] [Abstract][Full Text] [Related]
6. Beyond triple-negative breast cancer: the need to define new subtypes.
Constantinidou A; Jones RL; Reis-Filho JS
Expert Rev Anticancer Ther; 2010 Aug; 10(8):1197-213. PubMed ID: 20735307
[TBL] [Abstract][Full Text] [Related]
7. Metastatic triple-negative breast cancer.
Rakha EA; Chan S
Clin Oncol (R Coll Radiol); 2011 Nov; 23(9):587-600. PubMed ID: 21524569
[TBL] [Abstract][Full Text] [Related]
8. BRACking news on triple-negative/basal-like breast cancers: how BRCA1 deficiency may result in the development of a selective tumor subtype.
Santarosa M; Maestro R
Cancer Metastasis Rev; 2012 Jun; 31(1-2):131-42. PubMed ID: 22101651
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas.
Rodríguez-Pinilla SM; Sarrió D; Honrado E; Hardisson D; Calero F; Benitez J; Palacios J
Clin Cancer Res; 2006 Mar; 12(5):1533-9. PubMed ID: 16533778
[TBL] [Abstract][Full Text] [Related]
10. Treatment of triple negative breast cancer (TNBC): current options and future perspectives.
De Laurentiis M; Cianniello D; Caputo R; Stanzione B; Arpino G; Cinieri S; Lorusso V; De Placido S
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S80-6. PubMed ID: 21129616
[TBL] [Abstract][Full Text] [Related]
11. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM; Zhang BN; Xuan LX; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of basal-like subtype in triple-negative breast cancer.
Yamamoto Y; Ibusuki M; Nakano M; Kawasoe T; Hiki R; Iwase H
Breast Cancer; 2009; 16(4):260-7. PubMed ID: 19701681
[TBL] [Abstract][Full Text] [Related]
13. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research.
Bosch A; Eroles P; Zaragoza R; Viña JR; Lluch A
Cancer Treat Rev; 2010 May; 36(3):206-15. PubMed ID: 20060649
[TBL] [Abstract][Full Text] [Related]
14. Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features.
Venkitaraman R
Expert Rev Anticancer Ther; 2010 Feb; 10(2):199-207. PubMed ID: 20131996
[TBL] [Abstract][Full Text] [Related]
15. PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis.
Aleskandarany MA; Rakha EA; Ahmed MA; Powe DG; Paish EC; Macmillan RD; Ellis IO; Green AR
Breast Cancer Res Treat; 2010 Jul; 122(1):45-53. PubMed ID: 19701705
[TBL] [Abstract][Full Text] [Related]
16. Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice.
Diaz LK; Cryns VL; Symmans WF; Sneige N
Adv Anat Pathol; 2007 Nov; 14(6):419-30. PubMed ID: 18049131
[TBL] [Abstract][Full Text] [Related]
17. Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics.
Kurebayashi J
Breast Cancer; 2009; 16(4):275-80. PubMed ID: 19408071
[TBL] [Abstract][Full Text] [Related]
18. Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.
Rennstam K; McMichael N; Berglund P; Honeth G; Hegardt C; Rydén L; Luts L; Bendahl PO; Hedenfalk I
Breast Cancer Res Treat; 2010 Jul; 122(2):315-24. PubMed ID: 19795205
[TBL] [Abstract][Full Text] [Related]
19. Pharmacotherapy of triple-negative breast cancer.
Arslan C; Dizdar O; Altundag K
Expert Opin Pharmacother; 2009 Sep; 10(13):2081-93. PubMed ID: 19640211
[TBL] [Abstract][Full Text] [Related]
20. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM
Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
